Delivery Order GS10F0012Y-HHSD2002014F60304

This federal contract award is for a prospective single-arm clinical trial to evaluate the immunogenicity of the Gardasil 9 HPV vaccine administered to female living donor kidney transplant recipients prior to transplantation. The objective is to assess vaccine-type-specific seroconversion rates at 12 months post-transplantation. The prime contractor is Northwestern University, with multiple subcontractors including the University of California, San Francisco; Cedars-Sinai Medical Center; Mayo...

This federal contract award, valued at $657,924.00, was issued by the Centers for Disease Control and Prevention (CDC) to Battelle Memorial Institute, a large nonprofit research and development organization, to conduct a "REASSESSMENT OF MONITORING THE IMPACT OF A PROPHYLACTIC HPV VACCINE". The award is a BPA Call issued under the Achieving Public Health Impact Through Research (APHITR) master BPA, allowing the CDC to task Battelle for specific research services. The contract does...

This is a $1,097,484.28 delivery order contract awarded by the Centers for Disease Control and Prevention (CDC) to Healthpartners Institute, a non-profit organization. The contract is for evaluating the risk of spontaneous abortion following administration of the 4-valent human papillomavirus (4vHPV) and 9-valent human papillomavirus (9vHPV) vaccines. The contract is part of the Vaccine Safety Datalink Project, a larger indefinite delivery, indefinite quantity (IDIQ) contract vehicle with the...

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded Merck Sharp & Dohme LLC, doing business as Merck, a $467,200.00 firm fixed-price purchase order to provide 4,000 doses of the FDA-approved Gardasil-9 vaccine. This vaccine contains virus-like particles for the HPV6/11/16/18/31/33/45/52/58 strains and an alum adjuvant. The contract is for a one-dose clinical trial and does not have a set-aside designation. Merck is a for-profit...

This firm fixed price delivery order, valued at $3,984,492, was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health within the Department of Health and Human Services, to Fundacion Inciensa for human papillomavirus (HPV) vaccine evaluation efforts in Costa Rica. The work furthers NCI's evaluation of single dose protection from prophylactic HPV vaccines and will involve conducting the next phase of HPV vaccine research in Costa Rica under a January 2023 end...

The Centers for Disease Control and Prevention awarded a $72,030 firm fixed price purchase order to CHU De Québec - Université Laval to support mathematical modeling for human papillomavirus (HPV) vaccination strategies. As the prime contractor, CHU De Québec - Université Laval will leverage their expertise in mathematical modeling to analyze different HPV vaccination approaches for the CDC. The project aims to help inform public health efforts to prevent HPV-related diseases like cervical...

<p>This is a $3,691,644.00 definitive contract awarded by a U.S. government agency to a prime contractor to develop early phase clinical trial protocols to evaluate the safety and immunogenicity of human papillomavirus virus-like particle (VLP) based vaccines. The contract has a completion date of September 30, 2008 and is a cost-no-fee pricing type contract. The place of performance is Baltimore, MD 21218, USA. The contract is not set aside for any specific business type.</p>

This $2,931,937 firm fixed-price delivery order was awarded to Fundacion Inciensa, a non-profit organization and foundation based in Costa Rica. The contract was awarded by the National Cancer Institute (NCI), a civilian agency under the U.S. Department of Health and Human Services, to support the &quot;Evaluation of Single Dose Protection Afforded by the Prophylactic HPV Vaccines&quot; program. The contract involves laboratory testing of biospecimens collected from participants of NCI's human...

This is a $4,392,506.00 definitive contract awarded by the U.S. Department of Health and Human Services (HHS) to the University of California, Irvine (UC Irvine) for a Phase II chemoprevention clinical trial study to evaluate the effect of the HPV 16 vaccine. The contract does not have a set-aside designation. UC Irvine, a public research university, has extensive expertise in biomedical research and leverages its specialized facilities and faculty to deliver R&amp;D services to federal...

This is a delivery order awarded to Amerisourcebergen Drug Corp under a larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical. The order is for 4,565,179 units of the GARDASIL 9 vaccine, a pharmaceutical product used to prevent certain types of human papillomavirus (HPV) infections. The delivery order has a ceiling value of $8,857.24 and a firm fixed-price pricing structure. It has a period of performance through July 18, 2024. This contract...